VPC
Vestal Point Capital Portfolio holdings
AUM
$2.2B
1-Year Est. Return
36.26%
1 Year Est. Return
+36.26%
AUM
$2.2B
AUM Growth
+$305M
(+16%)
Holding
95
Top Buys
| 1 | +$84.9M | |
| 2 | +$79.5M | |
| 3 | +$56.2M | |
| 4 |
Repligen
RGEN
|
+$53.5M |
| 5 |
DexCom
DXCM
|
+$43.7M |
Top Sells
| 1 | +$203M | |
| 2 | +$124M | |
| 3 | +$123M | |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
+$92.3M |
| 5 |
Dianthus Therapeutics
DNTH
|
+$79.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Disc Medicine
IRON
$3.47B
| $33M | 1.49% |
500,000
+360,000
|
|
||
27
Nurix Therapeutics
NRIX
$1.93B
| $32.1M | 1.45% |
3,475,000
+1,475,000
|
|
||
28
Crinetics Pharmaceuticals
CRNX
$4.79B
| $31.2M | 1.41% |
750,000
-750,000
|
|
||
29
Celldex Therapeutics
CLDX
$1.83B
| $31.2M | 1.41% |
1,205,000
-545,000
|
|
||
30
Zymeworks
ZYME
$1.92B
| $30.1M | 1.36% |
1,765,000
+615,000
|
|
||
31
Danaher
DHR
$160B
| $29.7M | 1.34% |
150,000
+100,000
|
|
||
32
Revolution Medicines
RVMD
$15.3B
| $29.4M | 1.33% |
630,000
-570,000
|
|
||
|
RAPP
33
Rapport Therapeutics
RAPP
$1.44B
| $28.2M | 1.27% |
+950,000
|
|
||
34
Enliven Therapeutics
ELVN
$1B
| $23.7M | 1.07% |
1,160,000
+910,000
|
|
||
35
Geron
GERN
$868M
| $23.6M | 1.07% |
17,225,000
-6,550,000
|
|
||
|
BLTE
36
Belite Bio
BLTE
$5.3B
| $23.1M | 1.04% |
+312,500
|
|
||
37
Ultragenyx Pharmaceutical
RARE
$3.5B
| $22.6M | 1.02% |
+750,000
|
|
||
38
Vera Therapeutics
VERA
$3.18B
| $22.1M | 1% |
760,000
-2,340,000
|
|
||
39
Lexeo Therapeutics
LXEO
$713M
| $21.6M | 0.97% |
3,250,000
+21,839
|
|
||
40
Black Diamond Therapeutics
BDTX
$159M
| $21M | 0.95% |
5,550,000
-50,000
|
|
||
41
Day One Biopharmaceuticals
DAWN
$858M
| $18.9M | 0.85% |
2,675,000
-325,000
|
|
||
42
Solid Biosciences
SLDB
$457M
| $18.4M | 0.83% |
2,975,000
+1,470,000
|
|
||
43
Axsome Therapeutics
AXSM
$7.47B
| $18.2M | 0.82% |
+150,000
|
|
||
44
Taysha Gene Therapies
TSHA
$1.59B
| $18M | 0.81% |
5,500,000
+2,500,000
|
|
||
45
Apogee Therapeutics
APGE
$5.27B
| $16.9M | 0.76% |
+425,000
|
|
||
46
Savara
SVRA
$1.41B
| $14.3M | 0.65% |
4,015,000
-7,000,000
|
|
||
47
Bruker
BRKR
$6.86B
| $14.3M | 0.65% |
440,000
-60,000
|
|
||
48
Regeneron Pharmaceuticals
REGN
$77.9B
| $14.1M | 0.63% |
+25,000
|
|
||
49
uniQure
QURE
$1.22B
| $13.1M | 0.59% |
225,000
-3,475,000
|
|
||
|
BBNX
50
Beta Bionics
BBNX
$1.31B
| $11.9M | 0.54% |
600,000
+50,000
|
|